GNI Group Ltd. (TSE: 2160)
Health Care · Biotechnology · JP
¥3,200.00
-3.18% today · +34.4% 1Y
GNI Group Ltd. (TSE: 2160) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.33B and employs 990 people.
Over the last twelve months the share price has gained 34.4%, trading between 2.11K and 3.74K.
Tweenvest scores GNI Group Ltd. across four factors: quality 60/100, value 51/100, growth 76/100. Its strongest factor is growth.
2160 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.33B
- Revenue (TTM)
- $163.19M
- P/E
- —
- EPS
- -96.36
- Dividend yield
- —
- Beta (5Y)
- 1.19
- 52-week high
- ¥3,740.00
- 52-week low
- ¥2,112.00
- Avg volume (3M)
- —
- Shares outstanding
- 65.84M
- Employees
- 990
- Next earnings
- —
About GNI Group Ltd.
GNI Group Ltd. is a global biopharmaceutical enterprise dedicated to the research, development, manufacturing, and commercialization of both modern pharmaceuticals and traditional Chinese medicines. The company's lead product, Etuary, is currently available for the treatment of idiopathic pulmonary fibrosis. Beyond this, Etuary is undergoing further clinical evaluation: it is in Phase III trials for connective tissue disease-associated interstitial lung disease, and in Phase II along with a pre-Phase III pilot study for radiation pneumonitis. Investigations are also underway for its application in diabetic nephropathy. GNI Group Ltd.'s pipeline additionally features F351, which is in Phase II development for liver fibrosis; F573, an early-stage compound in pre-clinical testing for acute-on-chronic liver failure; and Tamibarotene, intended for the treatment of acute promyelocytic leukemia. Established in 2001, the company's headquarters are located in Tokyo, Japan.
- ISIN
- JP3386370005
- Founded
- 2001
- Listed since
- Aug 31, 2007
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Idorsia LtdSWX: IDIA | $1.36B | CHF4.20 | -5.83% |
| GenFleet Therapeutics (Shanghai) Inc.SEHK: 2595 | $1.35B | HK$28.60 | -10.46% |
| Pharma Mar, S.A.BME: PHM | $1.35B | €68.30 | -1.66% |
| BeBetter Med Inc.SHSE: 688759 | $1.35B | CN¥20.05 | -7.56% |
| Biotest GmbH & Co. KGaAHMSE: BIO0 | $1.33B | €30.00 | -9.64% |
| Everest Medicines LimitedSEHK: 1952 | $1.33B | HK$29.60 | +3.35% |
| Ascentage Pharma Group InternationalSEHK: 6855 | $1.32B | HK$28.22 | -3.36% |
| Damora Therapeutics, Inc.NasdaqCM: DMRA | $1.30B | $20.22 | -4.08% |
Figures last refreshed Oct 11, 2026.